A new prescription pattern has been established for psoriasis patients who achieve complete response after three administrations of guselkumab.

Further administrations of the drug will occur on an as-needed basis, based on the reappearance of skin lesions.

This protocol has been shown to be safe and effective for long-term use, with results comparable to therapeutic guidelines. On-going research is focused on identifying patients who may benefit from new dosage optimisation strategies.